The FDA issued warning concerning the 3 Hepatitis drugs, namely, AbbVie’s Mavyret (glecaprevir/pibrentasvir), Merck’s Zepatier (elbasvir/grazoprevir) or Gilead’s Vosevi (sofosbuvir/velpatasvir/voxilaprevir), which was initially thought to improve the condition of the patients with chronic hepatitis C with moderate to severe liver impairment, but has now seemed to be worsening the liver functions of these patients with rare cases of liver failures.

As of 2018, the FDA noted about 63 patient with worsening liver functions in its adverse event reporting system with 46 for Mavyret, 14 for Zepatier, and three for Vosevi. Also, some of the cases led to liver failure and eight cases reported deaths. However, the FDA has not given red flag to the patients to stop using these drugs, but, it has suggested them to contact the health care professionals, in case they develop any severe sign of liver failure symptoms like fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools, as these may be the signs of liver injury.